---
title: "Gushengtang reshapes board with new audit chair as veteran director exits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286117482.md"
description: "Gushengtang Holdings Limited announced board changes effective May 12, 2026, with independent non-executive director Li Tie resigning as audit committee chair to focus on other commitments. Finance scholar Chang Xin has been appointed as his replacement, expected to enhance financial oversight and governance. The company aims to strengthen investor confidence and align with international best practices. The latest analyst rating for Gushengtang stock (HK:2273) is a Sell with a price target of HK$24.50. Gushengtang operates in the healthcare sector, focusing on traditional Chinese medicine."
datetime: "2026-05-12T13:25:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286117482.md)
  - [en](https://longbridge.com/en/news/286117482.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286117482.md)
---

# Gushengtang reshapes board with new audit chair as veteran director exits

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Gushengtang Holdings Limited ( (HK:2273) ) has shared an announcement.

Gushengtang Holdings has announced board-level changes effective May 12, 2026, with the resignation of independent non-executive director Li Tie, who is stepping down as chair of the audit committee and as a member of the remuneration committee to focus on other business commitments. The board emphasized that Li departs without disagreement and expressed gratitude for his contributions since joining the company in 2021.

To fill the governance gap, the company has appointed finance scholar Chang Xin as an independent non-executive director, audit committee chair and remuneration committee member, bringing extensive academic, research and industry experience from institutions such as Nanyang Technological University, the University of Cambridge and roles in asset management. His appointment is expected to bolster the company’s financial oversight and board independence, potentially strengthening investor confidence and aligning governance with international best practices.

The most recent analyst rating on (HK:2273) stock is a Sell with a HK$24.50 price target. To see the full list of analyst forecasts on Gushengtang Holdings Limited stock, see the HK:2273 Stock Forecast page.

**More about Gushengtang Holdings Limited**

Gushengtang Holdings Limited is a Cayman Islands-incorporated company listed in Hong Kong, operating in the healthcare sector with a focus likely on traditional Chinese medicine and related medical services. The group structure includes subsidiaries and consolidated affiliated entities, reflecting a multi-entity platform serving patients and healthcare consumers in Mainland China and broader Asian markets.

**Average Trading Volume:** 1,411,005

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$6.83B

Learn more about 2273 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02273.HK](https://longbridge.com/en/quote/02273.HK.md)

## Related News & Research

- [BOCOM International Holdings Company Reaffirms Their Buy Rating on Gushengtang Holdings Limited (2273)](https://longbridge.com/en/news/281675198.md)
- [ELFI offers new private student loan alternative for medical and healthcare students facing federal loan changes](https://longbridge.com/en/news/286929682.md)
- [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md)
- [Gushengtang to Raise US$110 Million via Premium-Priced Convertible Bonds for AI-Driven TCM Push](https://longbridge.com/en/news/273714170.md)
- [Virtuix Expands Into AI-Assisted Neurodivergent Therapy Through Rutgers University Collaboration | VTIX Stock News](https://longbridge.com/en/news/287075316.md)